{
  "schemaVersion": 2,
  "eyebrow": "Emergency Medicine",
  "title": "Adult Diabetic Ketoacidosis",
  "summary": "Adult diabetic ketoacidosis requires immediate recognition of insulin deficiency, volume depletion, electrolyte derangement, and its precipitant. This review focuses on rapid diagnostic confirmation, diabetes-type reassessment, safe insulin-dependent care, and prevention of recurrent hyperglycemic crises using currently supplied evidence.",
  "seoDescription": "Adult diabetic ketoacidosis: diagnosis, diabetes classification, insulin dependence, monitoring, and prevention of recurrent hyperglycemic crises for U.S. clinicians.",
  "clinicalQuestion": "How should clinicians recognize diabetic ketoacidosis, clarify diabetes type, and prevent recurrent hyperglycemic crises in adults?",
  "specialty": "Emergency Medicine and Endocrinology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "adult diabetic ketoacidosis",
    "DKA",
    "hyperglycemic crisis",
    "type 1 diabetes",
    "type 2 diabetes",
    "diabetes classification"
  ],
  "keyTakeaways": [
    "In an adult with classic hyperglycemic symptoms or hyperglycemic crisis, random plasma glucose of at least 200 mg/dL establishes diabetes; DKA requires urgent treatment and evaluation of the underlying diabetes type. [17]",
    "Do not assume an adult has type 2 diabetes because of age or adiposity: type 1 diabetes occurs at all ages, and adult misclassification is common. [17]",
    "Younger age, lower BMI, unintentional weight loss, ketoacidosis, and marked hyperglycemia favor type 1 diabetes; GAD antibody testing followed by IA-2 and/or ZnT8 testing can support classification when phenotype overlaps. [17]",
    "C-peptide helps classify insulin-treated adults when diabetes type remains uncertain, but should not be tested within 2 weeks after a hyperglycemic emergency. [17]",
    "Patients with type 1 diabetes require uninterrupted basal insulin during acute illness, hospitalization, fasting, and procedures because withholding insulin risks ketosis and DKA. [14]"
  ],
  "sections": [
    {
      "id": "clinical-priority",
      "eyebrow": "Immediate assessment",
      "heading": "Treat suspected DKA as an insulin-deficient emergency",
      "intro": "DKA should trigger simultaneous stabilization, biochemical assessment, and cause-directed evaluation.",
      "paragraphs": [
        "DKA reflects clinically consequential insulin deficiency with hyperglycemia, ketonemia, dehydration, acidemia, and electrolyte disturbance. It is classically associated with type 1 diabetes but can occur in insulinopenic type 2 diabetes, ketosis-prone type 2 diabetes, acute illness, missed insulin, and sodium-glucose cotransporter 2 inhibitor exposure. [17]",
        "The supplied sources do not provide a complete adult DKA fluid, insulin infusion, potassium replacement, bicarbonate, or transition-to-subcutaneous-insulin protocol. Therefore, institutionally approved hyperglycemic-crisis pathways and current specialty guidance should govern acute resuscitation and monitoring rather than extrapolation from the diabetes-management sources reviewed here. [17]"
      ],
      "bullets": [
        "Obtain plasma glucose and assess for hyperglycemic crisis; a random plasma glucose of at least 200 mg/dL with classic hyperglycemic symptoms or crisis meets diagnostic criteria for diabetes. [17]",
        "Obtain A1C when clinically useful to estimate antecedent glycemia; it does not replace acute glucose-based assessment in a hyperglycemic crisis. [17]",
        "Identify likely precipitants, including insulin interruption, infection or other acute illness, myocardial infarction, glucocorticoids, second-generation antipsychotics, and SGLT2 inhibitor use. [17]",
        "Document diabetes type and home insulin regimen early; in established type 1 diabetes, basal insulin must not be interrupted. [14]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical classification issues that change management after DKA resolution. [17]",
        "columns": [
          "Finding",
          "Clinical implication",
          "Next action"
        ],
        "rows": [
          [
            "Classic hyperglycemic symptoms or hyperglycemic crisis with random plasma glucose ≥200 mg/dL",
            "Diabetes is established clinically. [17]",
            "Treat the crisis and determine whether the patient has absolute or relative insulin deficiency. [17]"
          ],
          [
            "Adult with weight loss, ketoacidosis, marked hyperglycemia, younger age, or low BMI",
            "Features favor autoimmune type 1 diabetes but no single feature is definitive. [17]",
            "Order GAD antibody; if negative and suspicion remains, add IA-2 and/or ZnT8 antibodies where available. [17]"
          ],
          [
            "Insulin-treated adult with persistent uncertainty about diabetes type",
            "C-peptide may clarify endogenous insulin secretion. [17]",
            "Use a random C-peptide with concurrent glucose within 5 hours of eating; avoid testing within 2 weeks after a hyperglycemic emergency. [17]"
          ],
          [
            "Obesity or metabolic syndrome with DKA",
            "Does not exclude type 1 diabetes; ketosis-prone type 2 diabetes is also possible. [17]",
            "Maintain insulin until classification and insulin requirement are clear. [17]"
          ]
        ]
      }
    },
    {
      "id": "diagnosis-and-classification",
      "eyebrow": "Diagnostic reasoning",
      "heading": "Reassess diabetes type after initial stabilization",
      "intro": "Misclassification can produce unsafe insulin withdrawal or delayed insulin initiation.",
      "paragraphs": [
        "Diabetes classification is often uncertain at presentation. Type 1 diabetes can occur at any age, obesity does not exclude autoimmune diabetes, and approximately 40% of adults with newly diagnosed type 1 diabetes may initially be misdiagnosed as having type 2 diabetes. [17]",
        "The most useful clinical features favoring type 1 diabetes are age younger than 35 years, BMI below 25 kg/m2, unintentional weight loss, ketoacidosis, and plasma glucose above 360 mg/dL at presentation. Family history, ketosis without acidosis, osmotic symptoms, and coexisting autoimmune disease are weaker discriminators. [17]",
        "For adults with overlapping phenotypic features, standardized islet autoantibody testing is recommended. GAD is the preferred first test; if negative, IA-2 and/or ZnT8 antibodies should be considered where available. A negative antibody test does not exclude type 1 diabetes. [17]"
      ],
      "bullets": [
        "Consider pancreatic diabetes in patients with acute or chronic pancreatitis, pancreatic surgery, pancreatic neoplasia, or exocrine pancreatic insufficiency; these patients may have loss of both insulin and glucagon secretion. [17]",
        "Consider monogenic diabetes when diabetes begins in the first 6 months of life, when early-onset diabetes follows an autosomal dominant pattern, or when phenotype is atypical for type 1 and type 2 diabetes. [17]",
        "In adults with suspected type 1 diabetes who are not receiving insulin, provide close monitoring and education so insulin can be started promptly if glycemia deteriorates. [17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Interpretation of C-peptide in insulin-treated adults with uncertain diabetes classification. [17]",
        "columns": [
          "Result or circumstance",
          "Interpretation",
          "Action"
        ],
        "rows": [
          [
            "Random C-peptide ≥600 pmol/L (≥1.8 ng/mL)",
            "Substantial endogenous insulin secretion; testing circumstances are less consequential. [17]",
            "Assess for type 2 diabetes, monogenic diabetes, or other nonautoimmune diabetes while integrating phenotype and autoantibody results. [17]"
          ],
          [
            "Random C-peptide <80 pmol/L (<0.24 ng/mL)",
            "Very low endogenous insulin secretion. [17]",
            "Treat as severe insulin deficiency; do not discontinue insulin. [17]"
          ],
          [
            "C-peptide 200–600 pmol/L (0.6–1.8 ng/mL)",
            "Usually consistent with type 1 diabetes or MODY, but may occur in insulin-treated type 2 diabetes. [17]",
            "Interpret with concurrent glucose, duration of diabetes, phenotype, and antibody testing. [17]"
          ],
          [
            "Within 2 weeks of hyperglycemic emergency",
            "Result may not be appropriate for classification. [17]",
            "Defer C-peptide testing until recovery. [17]"
          ]
        ]
      }
    },
    {
      "id": "acute-care-safety",
      "eyebrow": "Inpatient safety",
      "heading": "Protect against recurrent ketosis during transitions of care",
      "intro": "Insulin omission is a preventable driver of recurrent DKA in insulin-deficient diabetes.",
      "paragraphs": [
        "For people with type 1 diabetes, uninterrupted basal insulin is essential to prevent hyperglycemia and ketoacidosis during hospitalization, fasting, and procedures. This requirement should be explicit in admission orders, perioperative plans, and handoffs. [14]",
        "Inpatient self-management may be appropriate only for selected patients who can safely administer insulin, monitor glucose, count carbohydrates, and participate in decisions under supervision from clinicians knowledgeable in glycemic management. [14]",
        "Hyperglycemia with DKA can also arise in type 2 diabetes during severe illness, insulin omission, or exposure to drugs including SGLT2 inhibitors. Because SGLT2 inhibitors can be associated with DKA, review these agents during every DKA evaluation. [17]"
      ],
      "bullets": [
        "Before stopping intravenous insulin or changing treatment intensity, verify that the patient has a viable subcutaneous insulin plan, access to insulin and supplies, and education on deterioration and ketone-risk symptoms; supplied sources support the need for uninterrupted basal insulin in type 1 diabetes but do not specify transition timing or dosing. [14]",
        "If a personal insulin pump is used, unexplained persistent hyperglycemia should prompt assessment for infusion interruption or site failure; if glucose does not improve after a correction, use injected insulin and change the infusion site. [14]",
        "Consider social and financial barriers to insulin, food, transportation, monitoring supplies, and follow-up. These barriers can impair self-management and increase acute complication risk. [14]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "post-crisis-follow-up",
      "eyebrow": "Prevention",
      "heading": "Use follow-up to prevent the next hyperglycemic crisis",
      "intro": "Recurrent DKA prevention depends on insulin access, skills, monitoring, and timely phenotype clarification.",
      "paragraphs": [
        "Diabetes self-management education and support is a core element of diabetes care. CDC guidance emphasizes ongoing team-based support and notes that structured diabetes self-management education and support is associated with lower A1C and fewer complications. [22]",
        "A1C monitoring frequency should reflect stability of therapy and glycemic control. CDC advises testing every 3 months when treatment has changed or goals are not met and every 6 months when treatment and glycemic goals are stable. [13]",
        "For type 2 diabetes treated with metformin plus an SGLT2 inhibitor or GLP-1 agonist, ACP states that routine self-monitoring of blood glucose may be unnecessary in stable patients; this does not apply to insulin-dependent patients or those at risk for hypoglycemia or recurrent ketosis. [2]"
      ],
      "bullets": [
        "At post-DKA review, reconcile all insulin products, injection or pump technique, access to glucose and ketone monitoring, and prescription affordability. [14]",
        "Review sick-day and device-failure plans, including when to seek urgent care for persistent hyperglycemia, vomiting, dehydration, or suspected ketosis; the sources establish these as clinically relevant risks but do not specify a universal outpatient ketone threshold. [14]",
        "Screen for psychosocial distress, depression, and barriers to care, especially after recurrent DKA or medication rationing. [14]",
        "For adults with type 2 diabetes and inadequate control despite metformin and lifestyle measures, ACP recommends adding either an SGLT2 inhibitor or GLP-1 agonist; choose SGLT2 inhibitors preferentially with heart failure or chronic kidney disease and GLP-1 agonists when stroke risk or weight loss is a major priority. [2]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "limits-of-evidence",
      "eyebrow": "Evidence limitation",
      "heading": "What the supplied evidence does not support",
      "intro": "Avoid false precision when source material does not contain acute-care protocol details.",
      "paragraphs": [
        "The provided search results include current diabetes diagnostic and classification guidance, longitudinal type 1 diabetes management, and general diabetes-care resources, but do not include a dedicated adult DKA consensus guideline or FDA labeling for insulin and adjunctive agents. Accordingly, they do not support publishing exact intravenous fluid choice or rate, insulin infusion dose, potassium replacement thresholds, bicarbonate criteria, phosphate therapy, anion-gap transition criteria, or ICU disposition thresholds. [14][17]",
        "Acute DKA care should therefore follow a current, locally adopted adult hyperglycemic-crisis protocol with endocrine and critical-care consultation as appropriate. Diabetes classification and recurrent-crisis prevention should proceed in parallel with acute stabilization. [14][17]"
      ],
      "bullets": [],
      "subsections": [],
      "table": null
    }
  ],
  "faq": [
    {
      "question": "Can an adult with obesity and DKA still have type 1 diabetes?",
      "answer": "Yes. Obesity does not exclude type 1 diabetes. In adults with DKA or an overlapping phenotype, evaluate clinical features, islet autoantibodies, and—after recovery when appropriate—C-peptide before reducing or discontinuing insulin. [17]"
    },
    {
      "question": "When should C-peptide be measured after DKA?",
      "answer": "Do not measure C-peptide within 2 weeks of a hyperglycemic emergency. In insulin-treated patients with uncertain diabetes type, a random sample with concurrent glucose within 5 hours of eating can help classify endogenous insulin secretion after recovery. [17]"
    },
    {
      "question": "Should basal insulin be held when an adult with type 1 diabetes is fasting or hospitalized?",
      "answer": "No. Type 1 diabetes requires uninterrupted basal insulin to prevent hyperglycemia and ketoacidosis, including during hospitalization, fasting, and procedures. [14]"
    },
    {
      "question": "What diabetes medications should be reviewed in every DKA presentation?",
      "answer": "Review all insulin access and adherence, recent glucocorticoids or second-generation antipsychotics, and SGLT2 inhibitor exposure. DKA can occur in insulinopenic type 2 diabetes and has been associated with SGLT2 inhibitor use. [17]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Drug Dosing Recommendations for All Patients: A Roadmap ...",
      "detail": "ascpt.onlinelibrary.wiley.com",
      "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923",
      "authors": "ascpt.onlinelibrary.wiley.com",
      "host": "ascpt.onlinelibrary.wiley.com"
    },
    {
      "number": 2,
      "title": "Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11614146",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 3,
      "title": "Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38639546",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 4,
      "title": "Quality of Care in Adults With Diabetes - Diabetes in America - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK612584",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 5,
      "title": "A review of the quality of current diabetes clinical practice guidelines - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6645402",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 6,
      "title": "Recent Updates to Clinical Practice Guidelines for Diabetes ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8901964",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 7,
      "title": "Introduction and Methodology: Standards of Care in Diabetes—2026 - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12690168",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 8,
      "title": "Type 2 diabetes in adults: management - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK553486",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 9,
      "title": "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27219496",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 10,
      "title": "6. Glycemic Goals and Hypoglycemia: Standards of Care in ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S006&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 11,
      "title": "16. Diabetes Care in the Hospital: Standards of Care in ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc24-S016&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 12,
      "title": "Diabetes - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK551501",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 13,
      "title": "Your Diabetes Care Schedule",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/diabetes/treatment/your-diabetes-care-schedule.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov"
    },
    {
      "number": 14,
      "title": "The Management of Type 1 Diabetes - Endotext - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279114",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 15,
      "title": "2. Classification and Diagnosis of Diabetes: Standards of ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/45/Supplement_1/S17/138925/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 16,
      "title": "Diagnosis and Classification of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 17,
      "title": "2. Diagnosis and Classification of Diabetes: Standards of Care ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 18,
      "title": "2. Classification and Diagnosis of Diabetes",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/40/Supplement_1/S11/36898/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 19,
      "title": "NCT00081328 | Treatment Options for Type 2 Diabetes in ...",
      "detail": "clinicaltrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT00081328",
      "authors": "clinicaltrials.gov",
      "host": "clinicaltrials.gov"
    },
    {
      "number": 20,
      "title": "Type 2 diabetes in adults: management | Guidance",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng28",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 21,
      "title": "Overview | Type 1 diabetes in adults: diagnosis and management  | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng17",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 22,
      "title": "Clinical Guidance for Diabetes",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/diabetes/hcp/clinical-guidance/index.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov"
    },
    {
      "number": 23,
      "title": "Management of Diabetes",
      "detail": "www.who.int",
      "url": "https://www.who.int/southeastasia/activities/management-of-diabetes",
      "authors": "www.who.int",
      "host": "www.who.int"
    },
    {
      "number": 24,
      "title": "Considerations for Blood Glucose Monitoring and Insulin Administration | Injection Safety | CDC",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/injection-safety/hcp/infection-control/index.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Drug Dosing Recommendations for All Patients: A Roadmap ...",
      "detail": "ascpt.onlinelibrary.wiley.com",
      "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923",
      "authors": "ascpt.onlinelibrary.wiley.com",
      "host": "ascpt.onlinelibrary.wiley.com",
      "snippet": "FDA has expected companies to perform PK studies in patients with either renal and/or hepatic impairment to determine if dosing adjustment is",
      "score": 0.5332765
    },
    {
      "number": 2,
      "title": "Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11614146",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium–glucose cotransporter-2 (S",
      "score": 0.7872945
    },
    {
      "number": 3,
      "title": "Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38639546",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "Methods: This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotranspo",
      "score": 0.77179235
    },
    {
      "number": 4,
      "title": "Quality of Care in Adults With Diabetes - Diabetes in America - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK612584",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "This article reviews the evidence behind current quality metrics and evaluates how well diabetes care in the United States meets high-quality standards at the individual and organizational levels. Clinical recommendations for diabetes focus on managing risk factors to prevent and treat microvascular",
      "score": 0.63288915
    },
    {
      "number": 5,
      "title": "A review of the quality of current diabetes clinical practice guidelines - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6645402",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "2008 to 2013. After an initial screening of these records, 146 were found to be guidelines related to diabetes. Inclusion and exclusion criteria were used to further refine the search and obtain a feasible number of guidelines for appraisal. Inclusion criteria for selected guidelines included 1) foc",
      "score": 0.6155738
    },
    {
      "number": 6,
      "title": "Recent Updates to Clinical Practice Guidelines for Diabetes ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8901964",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "53.Holt RI, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, _et al_. The management of type 1 diabetes in adults: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). _Diabetes Care_. 2021. 44:2589-625. doi: 10.2337/d",
      "score": 0.5709301
    },
    {
      "number": 7,
      "title": "Introduction and Methodology: Standards of Care in Diabetes—2026 - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12690168",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "The Standards of Care is internally reviewed by the ADA Medical Affairs scientific team for methodological rigor, accuracy, clarity, and implementation; the Standards of Care then undergoes external peer review, ADA leadership review, and ADA Board of Directors review and approval.\n\n## Scope of the ",
      "score": 0.498609
    },
    {
      "number": 8,
      "title": "Type 2 diabetes in adults: management - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK553486",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "This guideline contains recommendations for managing type 2 diabetes in adults, and focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications. The guideline does not cover diagnosis, secondary diabetes, typ",
      "score": 0.49611887
    },
    {
      "number": 9,
      "title": "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27219496",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "Management BLOSSOM = Behavioral Modification and Lorcaserin Second Study for Obesity Management BMI = body mass index BP = blood pressure C-SSRS = Columbia Suicidality Severity Rating Scale CAD = coronary artery disease CARDIA = Coronary Artery Risk Development in Young Adults CBT = cognitive behavi",
      "score": 0.35985944
    },
    {
      "number": 10,
      "title": "6. Glycemic Goals and Hypoglycemia: Standards of Care in ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S006&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA's current clinical practice recommendations and is",
      "score": 0.27213743
    },
    {
      "number": 11,
      "title": "16. Diabetes Care in the Hospital: Standards of Care in ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc24-S016&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA's current clinical practice recommendations and is",
      "score": 0.270038
    },
    {
      "number": 12,
      "title": "Diabetes - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK551501",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "According to the American Diabetes Association (ADA), a diagnosis of diabetes is through any of the following: An HbA1c level of 6.5% or higher; A fasting plasma glucose level of 126 mg/dL (7.0 mmol/L) or higher (no caloric intake for at least 8 hours); A two-hour plasma glucose level of 11.1 mmol/L",
      "score": 0.20673421
    },
    {
      "number": 13,
      "title": "Your Diabetes Care Schedule",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/diabetes/treatment/your-diabetes-care-schedule.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov",
      "snippet": "Doctor visit. If you're having trouble meeting your treatment goals, visit your doctor every 3 months. Your blood pressure and weight will be checked, and your self-care plan and medicines will be reviewed. Ask your doctor to check your feet if you've ever had diabetes-related foot problems.\n\n## Eve",
      "score": 0.17229746
    },
    {
      "number": 14,
      "title": "The Management of Type 1 Diabetes - Endotext - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279114",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Thus, treatment goals should be reassessed and individualized based on patient factors. Older patients with long life expectancy and little comorbidity should have treatment targets similar to those of middle-aged or younger adults. In patients with multiple comorbid conditions, treatment targets ma",
      "score": 0.15059036
    },
    {
      "number": 15,
      "title": "2. Classification and Diagnosis of Diabetes: Standards of ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/45/Supplement_1/S17/138925/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "The A1C test, with a diagnostic threshold of ≥6.5% (48 mmol/mol), diagnoses only 30% of the diabetes cases identified collectively using A1C,",
      "score": 0.56719416
    },
    {
      "number": 16,
      "title": "Diagnosis and Classification of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "recommended the use of the A1C test to diagnose diabetes, with a threshold of ≥6.5%, and ADA affirms this decision.",
      "score": 0.5357549
    },
    {
      "number": 17,
      "title": "2. Diagnosis and Classification of Diabetes: Standards of Care ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "GDM, gestational diabetes mellitus; GLT, glucose load test; OGTT, oral glucose tolerance test.\n\n\\American College of Obstetricians and Gynecologists (ACOG) recommends any of the commonly used thresholds of 130, 135, or 140 mg/dL for the 1-h 50-g GLT (204).\n\n†ACOG notes that one elevated value can be",
      "score": 0.5324014
    },
    {
      "number": 18,
      "title": "2. Classification and Diagnosis of Diabetes",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/40/Supplement_1/S11/36898/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "Criteria for testing for diabetes or prediabetes in asymptomatic adults. 1. Testing should be considered in overweight or obese (BMI ≥25 kg",
      "score": 0.43885794
    },
    {
      "number": 19,
      "title": "NCT00081328 | Treatment Options for Type 2 Diabetes in ...",
      "detail": "clinicaltrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT00081328",
      "authors": "clinicaltrials.gov",
      "host": "clinicaltrials.gov",
      "snippet": "Diabetes by ADA criteria (laboratory determinations of fasting glucose ≥ 126 mg/dL, random glucose ≥ 200 mg/dL, or two-hour OGTT glucose ≥ 200 mg/dL) documented and confirmed in medical record. For patients diagnosed with diabetes during screening who have a normal fasting glucose but an elevated tw",
      "score": 0.22617671
    },
    {
      "number": 20,
      "title": "Type 2 diabetes in adults: management | Guidance",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng28",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "You are here:\n\n# Type 2 diabetes in adults: management\n\n## Overview\n\nThis guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-t",
      "score": 0.7487387
    },
    {
      "number": 21,
      "title": "Overview | Type 1 diabetes in adults: diagnosis and management  | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng17",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "You are here:\n\n# Type 1 diabetes in adults: diagnosis and management\n\n## Overview\n\nThis guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and m",
      "score": 0.7161595
    },
    {
      "number": 22,
      "title": "Clinical Guidance for Diabetes",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/diabetes/hcp/clinical-guidance/index.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov",
      "snippet": "## Managing diabetes\n\n### Diabetes Standards of Care\n\nStay up to date on the latest Diabetes Standards of Care to ensure your patients are receiving timely, equitable, and high-quality care. These guidelines include screenings and management for diabetes and related complications, such as cardiovasc",
      "score": 0.4296453
    },
    {
      "number": 23,
      "title": "Management of Diabetes",
      "detail": "www.who.int",
      "url": "https://www.who.int/southeastasia/activities/management-of-diabetes",
      "authors": "www.who.int",
      "host": "www.who.int",
      "snippet": "### HEARTS D: diagnosis and management of type 2 diabetes\n\nThis new HEARTS – D module on Diagnosis and management of type 2 diabetes complements and expands the diabetes section of the HEARTS Technical Package...\n\nGuideline: sugars intake for adults and children\n\n### Guideline: sugars intake for adu",
      "score": 0.4126491
    },
    {
      "number": 24,
      "title": "Considerations for Blood Glucose Monitoring and Insulin Administration | Injection Safety | CDC",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/injection-safety/hcp/infection-control/index.html",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov",
      "snippet": "A .gov website belongs to an official government organization in the United States.\n\nA lock (  ) or  means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.\n\nCenters for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Pro",
      "score": 0.25930288
    }
  ],
  "publishedAt": "2026-08-20T23:34:07.251543Z",
  "updatedAt": "2026-08-20T23:34:07.251543Z",
  "readingMinutes": 5,
  "slug": "adult-diabetic-ketoacidosis"
}